Correction to: Vildagliptin Attenuates Huntington's Disease Through Activation of GLP-1 Receptor/PI3K/Akt/BDNF Pathway in 3-Nitropropionic Acid Rat Model.

Sayed, Noha H; Fathy, Nevine; Kortam, Mona A; Rabie, Mostafa A; Mohamed, Ahmed F; Kamel, Ahmed S

Sayed, Noha H; Fathy, Nevine; Kortam, Mona A; Rabie, Mostafa A; Mohamed, Ahmed F; Kamel, Ahmed S.

Afiliação

Sayed NH; Department of Biochemistry, Faculty of Pharmacy, Cairo University, Governorate, Giza, Egypt.
Fathy N; Department of Biochemistry, Faculty of Pharmacy, Cairo University, Governorate, Giza, Egypt. nevine.abdallah@pharma.cu.edu.eg.
Kortam MA; Department of Biochemistry, Faculty of Pharmacy, Cairo University, Governorate, Giza, Egypt.
Rabie MA; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Governorate, Giza, Egypt.
Mohamed AF; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Governorate, Giza, Egypt.
Kamel AS; Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Governorate, Giza, Egypt.

Neurotherapeutics ; 19(2): 686, 2022 Mar.

Article em En | MEDLINE | ID: mdl-35352287

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Neurotherapeutics Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Neurotherapeutics Ano de publicação: 2022 Tipo de documento: Article